Antonia DePace

A lack of understanding about renal cell carcinoma (RCC), clinical trials, and the diseases psychosocial impact may exist in patients living with the illness and their families.

A proportion of patients with myeloproliferative neoplasms were not prescribed medications needed for the management of comorbidities in the United Kingdom, a poster presented during the 2021 European Hematology Association Virtual Congress showed.

In patients with pre-immune checkpoint inhibitor-naïve advanced melanoma, treatment with the combination of lifileucel plus pembrolizumab, compared to pembrolizumab alone, increased the overall response rate.

The combination of cirmtuzumab and ibrutinib achieved high overall response rates in patients with mantle cell lymphoma or chronic lymphocytic leukemia who were treated in a phase 1/2 study.

lenvatinib plus pembrolizumab elicited a response in some patients with advanced colorectal cancer.